H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Evoke Pharma (EVOK) today. The company’s shares closed yesterday at $0.90, close to its 52-week low of $0.50.
Selvaraju commented:
“Valuation methodology and risks. We remain in a holding pattern until further clarity is obtained regarding the issues raised in the CRL and the degree to which they can be addressed near-term, as well as the timeline to potential resubmission of the Gimoti NDA and possible regulatory approval of the drug.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -11.2% and a 26.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and Stealth Biotherapeutics Corp.
The the analyst consensus on Evoke Pharma is currently a Hold rating.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.40 and a one-year low of $0.50. Currently, Evoke Pharma has an average volume of 793K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus.
